



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Jue, R.A., et al.

Appl. No. : 09/575,199

Filed : May 18, 2000

For : VASCULAR ENDOTHELIAL
GROWTH FACTOR DIMERS

Examiner : SPECTOR, L.

) Group Art Unit 1647

) I hereby certify that this correspondence and all
) marked attachments are being deposited with the
) United States Postal Service as first-class mail in
) an envelope addressed to: United States Patent
) and Trademark Office, P.O. Box 2327,
) Arlington, VA 22202, on

November 1, 2002

(Date)

James J. Mullen III, Ph.D., Reg. No. 44,957

AMENDMENT AND RESPONSE

RECEIVED

NOV 15 2002

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

TECH CENTER 1600/2800

Dear Sir:

In response to the Office Action mailed July 3, 2002, Applicant respectfully submits the following amendments and comments in connection with the above-captioned application. A one-month extension of time is requested for this amendment and response.

IN THE SPECIFICATION:

**On pages 1 and 48, please amend the title to read as follows: "VASCULAR
ENDOTHELIAL GROWTH FACTOR DIMER VARIANTS"**

Please amend the paragraph 18, line 33 to page 19, line 11 as follows:

C/ In *E. coli*, the VEGF₁₂₁ monomers typically accumulate in the form of inclusion bodies, and need to be solubilized, refolded, dimerized and purified. Methods for the recovery and refolding of VEGF isoforms from *E. coli* are known in the art. For example, refolding of certain VEGF isoforms following recombinant expression in *E. coli* is described in Christinger *et al.*, *Prot. Struc. Func. Genet. supra* (1996); Keyt *et al.*, *J. Biol. Chem.* 271:7788-7795 (1996); Cao *et al.*, *J. Biol. Chem.* 271:3154-3162 (1996); Siemeister *et al.*, *Biochem. Biophys. Res. Commun.* 222:249-255 (1996); and PCT Publication WO 96/06641. In a particularly preferred